Byotrol PLC Agreement with Solvay (9489U)
04 Agosto 2015 - 8:00AM
UK Regulatory
TIDMBYOT
RNS Number : 9489U
Byotrol PLC
04 August 2015
4th August 2015
Byotrol plc
JOINT COMMERCIAL & DEVELOPMENT AGREEMENT WITH SOLVAY TO
PROMOTE GROWTH
Byotrol, the specialist anti-microbial technology company, is
pleased to announce that it has signed an agreement to develop and
commercialise long-lasting biocidal products ("Agreement") with the
listed international chemical group Solvay SA ("Solvay").
As part of the Agreement Solvay will be making a significant
investment in Byotrol's technical cost base in the current
financial year. Assuming normal trading conditions prevail, the
Board expects the Company to report EBITDA break-even in the six
months to 31 March 2016.
Cooperation to drive innovation and growth
The Agreement formalises an already close technical relationship
between the Company and Solvay's subsidiary Solvay Novecare, a
world leader in specialty polymers and surfactants with an annual
turnover in excess of Euro 2 billion. It is built upon the joint
development of anti-microbials, combining the best of Byotrol's
long-lasting anti-microbial formulations and Solvay's world-leading
polymer and surfactant technologies (collectively the "Products").
The Company has already completed (and patented) one such product
for the EU consumer market and is actively marketing it jointly
with Solvay to customers.
Initially Byotrol will pool technical, commercial and sales
resource with Solvay Novecare in targeting Products at the EU
consumer market. Over time we expect to be expanding into other
geographies, into professional markets and in due course into
personal care markets too. The two parties will then be sharing
gross profit from any jointly-developed products.
David Traynor, Byotrol CEO commented: "We have been working
closely with Solvay for some time now and are delighted to
formalise our existing relationship, securing a strong endorsement
of our technology and development team from a world-class partner.
We will benefit greatly from Solvay's technical, regulatory and
commercial abilities, as well of course from its global sales
reach. This Agreement should be a clear inflection point in
Byotrol's growth."
Thierry Sclapari, Global Vice President, Home and Personal Care,
Solvay Novecare commented: "We see a big opportunity for our unique
polymer technologies in Byotrol's anti-microbial systems. We look
forward to taking our jointly-developed products to our customers
worldwide."
Enquiries:
Byotrol plc 01925 742 000
David Traynor - Chief Executive
Dawn Marshall - Group Marketing
Controller
finnCap Ltd 020 7220 0500
Geoff Nash / Carl Holmes
- Corporate Finance
Mia Gardner - Corporate Broking
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer
of residual antimicrobial technologies, maximising insights to
identify, develop, formulate and commercialise cutting-edge
antimicrobial technologies, delivered in direct sales and in
long-term licensing partnerships with consumer and professional
multi-nationals.
Our patented suite of technologies deliver powerful
broad-spectrum efficacy with residual performance optimised against
commonly occurring and industry-specific pathogens.
For more information, please go to www.byotrol.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRPKNDDABKDAFK
Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Lug 2023 a Lug 2024